
News|Videos|June 8, 2018 (Updated: May 8, 2025)
Evolving Use of ICIs and Targeted Tx in NSCLC and SCLC
Author(s)Apar Kishor Ganti, MD, MS
In this video, Apar Ganti, MD, highlights recent advances and studies presented at ASCO 2018 on management of NSCLC and SCLC with ICIs and targeted agents.
Advertisement
In this video, Apar Ganti, MD, highlights recent advances and studies presented at ASCO 2018 on management of NSCLC and SCLC with ICIs and targeted agents.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Related Content
Advertisement




Optimizing the Use of Hypofractionated Radiotherapy in Lung Cancer Care
Published: | Updated:

Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Grants Traditional Approval to Encorafenib in BRAF-Mutated CRC
2
FDA Grants Fast Track Designation to ART6043/Olaparib in BRCA-Mutated, HER2– Breast Cancer
3
Pembrolizumab Combo Yields Activity in Recurrent Gyn Clear Cell Carcinoma
4
Nivolumab/Chemo Yields Long-Term Survival in Advanced Gastric Cancers
5








































